CFDE Data Portal | Search C10orf88B

	Label	Description
	C10orf88B Gene (Entity type)	ENSG00000293310 - C10orf88B (pseudogene)
	GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 cisplatin 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 cisplatin 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115550 BRD4 inhibition 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 10 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 etoposide leukocyte 4 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS

C10orf88B

ENSG00000293310 - C10orf88B (pseudogene)

GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

A Gene Set from LINCS

GSE146982 metformin 4 v 5 human dn

A Gene Set from LINCS

GSE229973 cisplatin 3 v 5 human up

A Gene Set from LINCS

GSE229973 cisplatin 3 v 7 human up

A Gene Set from LINCS

GSE115550 BRD4 inhibition 2 v 1 human up

A Gene Set from LINCS

GSE216540 fulvestrant 10 v 6 human dn

A Gene Set from LINCS

GSE120612 etoposide leukocyte 4 v 2 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.